Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats

Fernanda R.C. Giachini, David A. Osmond, Shali Zhang, Fernando S. Carneiro, Victor V. Lima, Edward W. Inscho, R Clinton Webb, Rita C. Tostes

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The P2Y12 receptor antagonist clopidogrel blocks platelet aggregation, improves systemic endothelial nitric oxide bioavailability and has anti-inflammatory effects. Since P2Y12 receptors have been identified in the vasculature, we hypothesized that clopidogrel ameliorates AngII (angiotensin II)-induced vascular functional changes by blockade of P2Y12 receptors in the vasculature. Male Sprague-Dawley rats were infused with AngII (60 ng/min) or vehicle for 14 days. The animals were treated with clopidogrel (10 mg · kg-1 of body weight · day-1) or vehicle. Vascular reactivity was evaluated in second-order mesenteric arteries. Clopidogrel treatment did not change systolic blood pressure [(mmHg) control-vehicle, 117±7.1 versus control-clopidogrel, 125±4.2; AngII-vehicle, 197±10.7 versus AngII-clopidogrel, 198±5.2], but it normalized increased phenylephrine-induced vascular contractions [(%KCl) vehicle-treated, 182.2±18% versus clopidogrel, 133±14 %), as well as impaired vasodilation to acetylcholine [(%) vehicle-treated, 71.7±2.2 versus clopidogrel, 85.3±2.8) in AngII-treated animals. Vascular expression of P2Y12 receptor was determined by Western blot. Pharmacological characterization of vascular P2Y12 was performed with the P2Y12 agonist 2-MeS-ADP [2-(methylthio) adenosine 5′-trihydrogen diphosphate trisodium]. Although 2-MeS-ADP induced endothelium-dependent relaxation [(Emax %)=71±12 %) as well as contractile vascular responses (Emax %=83±12 %), these actions are not mediated by P2Y12 receptor activation. 2-MeS-ADP produced similar vascular responses in control and AngII rats. These results indicate potential effects of clopidogrel, such as improvement of hypertension-related vascular functional changes that are not associated with direct actions of clopidogrel in the vasculature, supporting the concept that activated platelets contribute to endothelial dysfunction, possibly via impaired nitric oxide bioavailability.

Original languageEnglish (US)
Pages (from-to)463-471
Number of pages9
JournalClinical Science
Volume118
Issue number7
DOIs
StatePublished - Jan 27 2010

Fingerprint

clopidogrel
Mesenteric Arteries
Angiotensin II
Blood Vessels
Biological Availability
Nitric Oxide
Purinergic P2Y Receptor Antagonists
Blood Pressure

Keywords

  • ADP
  • Angiotensin II
  • Clopidogrel
  • Endothelium
  • Hypertension
  • Mesenteric artery
  • P2Y receptor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Giachini, F. R. C., Osmond, D. A., Zhang, S., Carneiro, F. S., Lima, V. V., Inscho, E. W., ... Tostes, R. C. (2010). Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats. Clinical Science, 118(7), 463-471. https://doi.org/10.1042/CS20090392

Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats. / Giachini, Fernanda R.C.; Osmond, David A.; Zhang, Shali; Carneiro, Fernando S.; Lima, Victor V.; Inscho, Edward W.; Webb, R Clinton; Tostes, Rita C.

In: Clinical Science, Vol. 118, No. 7, 27.01.2010, p. 463-471.

Research output: Contribution to journalArticle

Giachini, Fernanda R.C. ; Osmond, David A. ; Zhang, Shali ; Carneiro, Fernando S. ; Lima, Victor V. ; Inscho, Edward W. ; Webb, R Clinton ; Tostes, Rita C. / Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats. In: Clinical Science. 2010 ; Vol. 118, No. 7. pp. 463-471.
@article{19464079f625452fb066bab7fa6117dd,
title = "Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats",
abstract = "The P2Y12 receptor antagonist clopidogrel blocks platelet aggregation, improves systemic endothelial nitric oxide bioavailability and has anti-inflammatory effects. Since P2Y12 receptors have been identified in the vasculature, we hypothesized that clopidogrel ameliorates AngII (angiotensin II)-induced vascular functional changes by blockade of P2Y12 receptors in the vasculature. Male Sprague-Dawley rats were infused with AngII (60 ng/min) or vehicle for 14 days. The animals were treated with clopidogrel (10 mg · kg-1 of body weight · day-1) or vehicle. Vascular reactivity was evaluated in second-order mesenteric arteries. Clopidogrel treatment did not change systolic blood pressure [(mmHg) control-vehicle, 117±7.1 versus control-clopidogrel, 125±4.2; AngII-vehicle, 197±10.7 versus AngII-clopidogrel, 198±5.2], but it normalized increased phenylephrine-induced vascular contractions [({\%}KCl) vehicle-treated, 182.2±18{\%} versus clopidogrel, 133±14 {\%}), as well as impaired vasodilation to acetylcholine [({\%}) vehicle-treated, 71.7±2.2 versus clopidogrel, 85.3±2.8) in AngII-treated animals. Vascular expression of P2Y12 receptor was determined by Western blot. Pharmacological characterization of vascular P2Y12 was performed with the P2Y12 agonist 2-MeS-ADP [2-(methylthio) adenosine 5′-trihydrogen diphosphate trisodium]. Although 2-MeS-ADP induced endothelium-dependent relaxation [(Emax {\%})=71±12 {\%}) as well as contractile vascular responses (Emax {\%}=83±12 {\%}), these actions are not mediated by P2Y12 receptor activation. 2-MeS-ADP produced similar vascular responses in control and AngII rats. These results indicate potential effects of clopidogrel, such as improvement of hypertension-related vascular functional changes that are not associated with direct actions of clopidogrel in the vasculature, supporting the concept that activated platelets contribute to endothelial dysfunction, possibly via impaired nitric oxide bioavailability.",
keywords = "ADP, Angiotensin II, Clopidogrel, Endothelium, Hypertension, Mesenteric artery, P2Y receptor",
author = "Giachini, {Fernanda R.C.} and Osmond, {David A.} and Shali Zhang and Carneiro, {Fernando S.} and Lima, {Victor V.} and Inscho, {Edward W.} and Webb, {R Clinton} and Tostes, {Rita C.}",
year = "2010",
month = "1",
day = "27",
doi = "10.1042/CS20090392",
language = "English (US)",
volume = "118",
pages = "463--471",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "7",

}

TY - JOUR

T1 - Clopidogrel, independent of the vascular P2Y12 receptor, improves arterial function in small mesenteric arteries from AngII-hypertensive rats

AU - Giachini, Fernanda R.C.

AU - Osmond, David A.

AU - Zhang, Shali

AU - Carneiro, Fernando S.

AU - Lima, Victor V.

AU - Inscho, Edward W.

AU - Webb, R Clinton

AU - Tostes, Rita C.

PY - 2010/1/27

Y1 - 2010/1/27

N2 - The P2Y12 receptor antagonist clopidogrel blocks platelet aggregation, improves systemic endothelial nitric oxide bioavailability and has anti-inflammatory effects. Since P2Y12 receptors have been identified in the vasculature, we hypothesized that clopidogrel ameliorates AngII (angiotensin II)-induced vascular functional changes by blockade of P2Y12 receptors in the vasculature. Male Sprague-Dawley rats were infused with AngII (60 ng/min) or vehicle for 14 days. The animals were treated with clopidogrel (10 mg · kg-1 of body weight · day-1) or vehicle. Vascular reactivity was evaluated in second-order mesenteric arteries. Clopidogrel treatment did not change systolic blood pressure [(mmHg) control-vehicle, 117±7.1 versus control-clopidogrel, 125±4.2; AngII-vehicle, 197±10.7 versus AngII-clopidogrel, 198±5.2], but it normalized increased phenylephrine-induced vascular contractions [(%KCl) vehicle-treated, 182.2±18% versus clopidogrel, 133±14 %), as well as impaired vasodilation to acetylcholine [(%) vehicle-treated, 71.7±2.2 versus clopidogrel, 85.3±2.8) in AngII-treated animals. Vascular expression of P2Y12 receptor was determined by Western blot. Pharmacological characterization of vascular P2Y12 was performed with the P2Y12 agonist 2-MeS-ADP [2-(methylthio) adenosine 5′-trihydrogen diphosphate trisodium]. Although 2-MeS-ADP induced endothelium-dependent relaxation [(Emax %)=71±12 %) as well as contractile vascular responses (Emax %=83±12 %), these actions are not mediated by P2Y12 receptor activation. 2-MeS-ADP produced similar vascular responses in control and AngII rats. These results indicate potential effects of clopidogrel, such as improvement of hypertension-related vascular functional changes that are not associated with direct actions of clopidogrel in the vasculature, supporting the concept that activated platelets contribute to endothelial dysfunction, possibly via impaired nitric oxide bioavailability.

AB - The P2Y12 receptor antagonist clopidogrel blocks platelet aggregation, improves systemic endothelial nitric oxide bioavailability and has anti-inflammatory effects. Since P2Y12 receptors have been identified in the vasculature, we hypothesized that clopidogrel ameliorates AngII (angiotensin II)-induced vascular functional changes by blockade of P2Y12 receptors in the vasculature. Male Sprague-Dawley rats were infused with AngII (60 ng/min) or vehicle for 14 days. The animals were treated with clopidogrel (10 mg · kg-1 of body weight · day-1) or vehicle. Vascular reactivity was evaluated in second-order mesenteric arteries. Clopidogrel treatment did not change systolic blood pressure [(mmHg) control-vehicle, 117±7.1 versus control-clopidogrel, 125±4.2; AngII-vehicle, 197±10.7 versus AngII-clopidogrel, 198±5.2], but it normalized increased phenylephrine-induced vascular contractions [(%KCl) vehicle-treated, 182.2±18% versus clopidogrel, 133±14 %), as well as impaired vasodilation to acetylcholine [(%) vehicle-treated, 71.7±2.2 versus clopidogrel, 85.3±2.8) in AngII-treated animals. Vascular expression of P2Y12 receptor was determined by Western blot. Pharmacological characterization of vascular P2Y12 was performed with the P2Y12 agonist 2-MeS-ADP [2-(methylthio) adenosine 5′-trihydrogen diphosphate trisodium]. Although 2-MeS-ADP induced endothelium-dependent relaxation [(Emax %)=71±12 %) as well as contractile vascular responses (Emax %=83±12 %), these actions are not mediated by P2Y12 receptor activation. 2-MeS-ADP produced similar vascular responses in control and AngII rats. These results indicate potential effects of clopidogrel, such as improvement of hypertension-related vascular functional changes that are not associated with direct actions of clopidogrel in the vasculature, supporting the concept that activated platelets contribute to endothelial dysfunction, possibly via impaired nitric oxide bioavailability.

KW - ADP

KW - Angiotensin II

KW - Clopidogrel

KW - Endothelium

KW - Hypertension

KW - Mesenteric artery

KW - P2Y receptor

UR - http://www.scopus.com/inward/record.url?scp=74749100152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749100152&partnerID=8YFLogxK

U2 - 10.1042/CS20090392

DO - 10.1042/CS20090392

M3 - Article

VL - 118

SP - 463

EP - 471

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 7

ER -